Buy these ASX growth shares this week: experts

Lithium, technology, and sleep treatment shares are where analysts are telling growth investors to put their money…

| More on:
Broker looking at the share price on her laptop with green and red points in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors looking for ASX growth shares to buy might want to look at the three listed below.

These shares have been named as buys and tipped to climb meaningfully from current levels. Here's what you need to know:

Pilbara Minerals Ltd (ASX: PLS)

This first ASX growth share to buy could be Pilbara Minerals. It is one of the world's leading lithium miners with a collection of high quality assets that are generating significant free cash flow. So much so, the company recently declared its maiden dividend. And while recent pressure on lithium prices has weighed on sentiment, the team at Morgans believe prices could soon benefit from "demand in the Chinese market [increasing] from March onwards."

Morgans currently has an add rating and $4.70 price target on this lithium miner's shares.

Readytech Holdings Ltd (ASX: RDY)

Another ASX growth share to buy could be Readytech. It is a leading provider of mission-critical software-as-a-service (SaaS) solutions for the education, employment services, workforce management, government and justice sectors. Goldman Sachs is bullish on the company due to its attractive valuation and exposure to government software. It notes that the latter "has been a pocket of strength and resilience" and expects it to help "deliver mid-teens organic growth at an expanding profit margin through the cycle."

Goldman has a buy rating and $4.40 price target on its shares.

ResMed Inc. (ASX: RMD)

A final ASX growth share to buy could be ResMed. It is a medical device company with a focus on the sleep disorder treatment market. Goldman is also bullish on ResMed and believes it is well-placed for growth in the coming years. In fact, its analysts "currently model an EPS CAGR of +11% (FY23-26E), with potential upside depending on how competitive/regulatory dynamics develop."

Goldman has a buy rating and $38.00 price target on its shares.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ReadyTech and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended ReadyTech. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Person pointing at an increasing blue graph which represents a rising share price.
Growth Shares

2 ASX growth shares to snap up while they're still down

Brokers see plenty of upside for these mainstay sector picks.

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
Growth Shares

Why these ASX growth stocks could be much bigger in 2030 than today

These stocks have long growth runways and strong business models.

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Growth Shares

3 incredible ASX growth shares to buy and hold forever in 2026

True long-term investing means owning businesses you’d be happy to hold through volatility, uncertainty, and decades of change.

Read more »

Happy work colleagues give each other a fist pump.
Growth Shares

2 shares to buy hand over fist before the ASX 200 soars higher in 2026

These shares are highly rated by brokers for a reason. Here's what you need to know about them.

Read more »

Buy now written on a red key with a shopping trolley on an Apple keyboard.
Broker Notes

Experts rate these 2 ASX shares as buys this month!

Leading analysts say these stocks are a buy.

Read more »

Happy healthcare workers in a labs
Technology Shares

Prediction: CSL shares could soar past $270 in 2026

Here's what to expect from the Australian-based global biotechnology company this year.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Growth Shares

2 unstoppable ASX 200 stocks to buy in 2026 and hold forever

These blue chips could have very bright futures. Do you own them?

Read more »

A man sees some good news on his phone and gives a little cheer.
Growth Shares

5 incredible ASX growth stocks to buy for 2026

These growth stocks could be well-positioned for the long-term.

Read more »